The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ergasheva U.P.

Chazov National Medical Research Center of Cardiology

Panchenko E.P.

Chazov National Medical Research Center of Cardiology

Nikitin E.A.

Botkin Moscow City Clinical Hospital;
Russian Medical Academy of Continuous Professional Education

Atrial fibrillation and bleeding as complications of targeted therapy in chronic lymphocytic leukemia with impact on cardiovascular mortality

Authors:

Ergasheva U.P., Panchenko E.P., Nikitin E.A.

More about the authors

Journal: Russian Cardiology Bulletin. 2024;19(3): 16‑25

DOI: 10.17116/Cardiobulletin20241903116

Read: 1528 times

Download PDF (RU)
Contact the author
Table of contents

ATRIAL FIBRILLATION AND BLEEDING AS COMPLICATIONS OF TARGETED THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH IMPACT ON CARDIOVASCULAR MORTALITY
ATRIAL FIBRILLATION AND BLEEDING AS COMPLICATIONS OF TARGETED THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH IMPACT ON CARDIOVASCULAR MORTALITY

To cite this article:

Ergasheva UP, Panchenko EP, Nikitin EA. Atrial fibrillation and bleeding as complications of targeted therapy in chronic lymphocytic leukemia with impact on cardiovascular mortality. Russian Cardiology Bulletin. 2024;19(3):16‑25. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20241903116

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Fibrin mono­mer in diagnosis of cardiovascular diseases. Russian Cardiology Bulletin. 2024;(4-2):113-120
Phase II clinical trial of refralon tablets in patients with persistent atrial fibrillation and atrial flutter. The stru­cture and plan of the study. Russian Cardiology Bulletin. 2024;(4-2):182-187
Refralon for drug-induced cardioversion of atrial fibrillation in patients with coro­nary artery disease. Russian Cardiology Bulletin. 2024;(4-2):188-196
Imme­diate outcomes of simu­ltaneous Cox-Maze procedure in patients with isolated and multivalvular heart defe­cts via right mini-thoracotomy. Piro­gov Russian Journal of Surgery. 2024;(12-2):18-24
Imme­diate and long-term resu­lts of the simu­ltaneous rhythm-converting procedure Cox-Maze IV in multivalvular correction. Piro­gov Russian Journal of Surgery. 2024;(12-2):25-34
Effi­ciency of complex medi­cal reha­bilitation after pulmonary enda­rterectomy. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):629-636
Cryoballoon abla­tion combined with antiarrhythmic therapy for atrial fibrillation in patients with cardiovascular como­rbidities. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):670-676
Obstructive sleep apnea syndrome as a predictor of atrial fibrillation. Russian Journal of Preventive Medi­cine. 2025;(1):109-114
Imme­diate resu­lts of mitral and aortic valve replacement with simu­ltaneous Cox-Maze IV procedure. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):28-33
The Rela­tionship of obstructive sleep apnea with paro­xysmal atrial fibrillation in women suffered coro­nary heart disease and arte­rial hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(2):61-66
Abstract:

Bruton tyrosine kinase inhibitors have dramatically changed the management of patients with chronic lymphocytic leukemia over the past decade. Despite clear efficacy of this class in the treatment of chronic lymphocytic leukemia, cardiovascular complications of Bruton tyrosine kinase inhibitors remain one of the most common reasons for discontinuation of anticancer therapy. This review focuses on cardiovascular complications of Bruton tyrosine kinase inhibitors and recommendations for the management of patients with chronic lymphocytic leukemia undergoing anticancer therapy.

Keywords:

chronic lymphocytic leukemia
Bruton tyrosine kinase inhibitors
Ibrutinib
Acalabrutinib
atrial fibrillation
bleeding

Authors:

Ergasheva U.P.

Chazov National Medical Research Center of Cardiology

Panchenko E.P.

Chazov National Medical Research Center of Cardiology

Nikitin E.A.

Botkin Moscow City Clinical Hospital;
Russian Medical Academy of Continuous Professional Education

Received:

20.06.2024

Accepted:

24.06.2024

Close metadata

References:

  1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. https://doi.org/10.1182/blood-2017-09-806398
  2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524-1537. https://doi.org/10.1016/S0140-6736(18)30422-7
  3. The Surveillance E and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Leukemia—Chronic Lymphocytic Leukemia (CLL). https://seer.cancer.gov/statfacts/html/clyl.html
  4. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’). Pod red. Kaprina AD, Starinskogo VV, Shakhzadovoi AO. M.: MNIOI im. P.A. Gertsena, filial FGBU «NMITs radiologii» Minzdrava Rossii; 2022. (In Russ.).
  5. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England Journal of Medicine. 2014;371(3):213-223.  https://doi.org/10.1056/nejmoa1400376
  6. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O’Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England Journal of Medicine. 2015;373(25):2425-2437. https://doi.org/10.1056/nejmoa1509388
  7. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. The New England Journal of Medicine. 2019;381(5):432-443.  https://doi.org/10.1056/nejmoa1817073
  8. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. The New England Journal of Medicine. 2018;379(26):2517-2528. https://doi.org/10.1056/nejmoa1812836
  9. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O’Brien S, Yenerel MN, Illés A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology. 2021;39(31):3441-3452. https://doi.org/10.1200/JCO.21.01210
  10. Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021;106(9):2364-2373. https://doi.org/10.3324/haematol.2020.272500
  11. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313-4320. https://doi.org/10.1182/blood-2011-06-338855
  12. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology-American Society of Hematology Education Program. 2012;2012:88-96.  https://doi.org/10.1182/asheducation-2013.1.692-b
  13. Deglesne PA, Chevallier N, Letestu R, Baran-Marszak F, Beitar T, Salanoubat C, Sanhes L, Nataf J, Roger C, Varin-Blank N, Ajchenbaum-Cymbalista F. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Research. 2006;66(14):7158-7166. https://doi.org/10.1158/0008-5472.can-06-0085
  14. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, Liou HC, Schattner EJ. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001;98(10):3050-3057. https://doi.org/10.1182/blood.v98.10.3050
  15. Xue C, Wang X, Zhang L, Qu Q, Zhang Q, Jiang Y. Ibrutinib in B-cell lymphoma: single fighter might be enough? Cancer Cell International. 2020;20:467.  https://doi.org/10.1186/s12935-020-01518-y
  16. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O’Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clinical Cancer Research. 2020;26(15):3918-3927. https://doi.org/10.1158/1078-0432.CCR-19-2856
  17. Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology. 2019;94(12):1353-1363. https://doi.org/10.1002/ajh.25638
  18. Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787-798.  https://doi.org/10.1038/s41375-019-0602-x
  19. Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107(9):2108-2120. https://doi.org/10.3324/haematol.2021.279012
  20. Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022;139(2):177-187.  https://doi.org/10.1182/blood.2021010845
  21. Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O’Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142(8):687-699.  https://doi.org/10.1182/blood.2022018818
  22. Mauro FR, Paoloni F, Molica S, Reda G, Trentin L, Sportoletti P, Marchetti M, Pietrasanta D, Marasca R, Gaidano G, Coscia M, Stelitano C, Mannina D, Di Renzo N, Ilariucci F, Liberati AM, Orsucci L, Re F, Tani M, Musuraca G, Gottardi D, Zinzani PL, Gozzetti A, Molinari A, Gentile M, Chiarenza A, Laurenti L, Varettoni M, Ibatici A, Murru R, Ruocco V, Del Giudice I, De Propris MS, Della Starza I, Raponi S, Nanni M, Fazi P, Neri A, Guarini A, Rigolin GM, Piciocchi A, Cuneo A, Foà R. Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. Cancers. 2021;14(1):207.  https://doi.org/10.3390/cancers14010207
  23. Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, Nanthakumar K, Calvillo-Argüelles O, Lee DS, Thavendiranathan P. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Journal of Clinical Oncology. 2021;39(31):3453-3462. https://doi.org/10.1200/jco.21.00693
  24. Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery EJ, Lee JH, Usenko G, Wang MH, Yu T, Jurczak W. Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. Hemasphere. 2022;6(12):e801. https://doi.org/10.1097/hs9.0000000000000801
  25. Baptiste F, Cautela J, Ancedy Y, Resseguier N, Aurran T, Farnault L, Escudier M, Ammar C, Gaubert M, Dolladille C, Barraud J, Peyrol M, Cohen A, Paganelli F, Alexandre J, Ederhy S, Thuny F. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6(1):e001049. https://doi.org/10.1136/openhrt-2019-001049
  26. Nikitin EA, Dmitrieva EA, Panteleev MA, Emelina EI, Ivanova VL, Kochkareva YuB, Arshanskaya EG, Lazarev IE, Markova EE, Mukha LA, Novitskaya NG, Pankrashkina MM, Glazunova VV, Shubina AV, Chernysh SA, Khuazheva NK, Naumova EV, Lugovskaya SA, Pochtar ME, Obukhova TN, Vinogradova OYu, Gendlin GE, Ptushkin VV. Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia. Klinicheskaja-onkogematologija. 2017;10(3):271-281. (In Russ.). https://doi.org/10.21320/2500-2139-2017-10-3-271-281
  27. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829-3830. https://doi.org/10.1182/blood-2014-10-604272
  28. Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, Iwamoto Y, Wojtkiewicz G, Cetinbas M, Schloss MJ, Tedeschi J, Lebrun-Vignes B, Lundby A, Sadreyev RI, Moslehi J, Nahrendorf M, Ellinor PT, Milan DJ. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation. 2020;142(25):2443-2455. https://doi.org/10.1161/circulationaha.120.049210
  29. Pretorius L, Du XJ, Woodcock EA, Kiriazis H, Lin RC, Marasco S, Medcalf RL, Ming Z, Head GA, Tan JW, Cemerlang N, Sadoshima J, Shioi T, Izumo S, Lukoshkova EV, Dart AM, Jennings GL, McMullen JR. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. The American Journal of Pathology. 2009;175(3):998-1009. https://doi.org/10.2353/ajpath.2009.090126
  30. Jiang L, Li L, Ruan Y, Zuo S, Wu X, Zhao Q, Xing Y, Zhao X, Xia S, Bai R, Du X, Liu N, Ma CS. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm. 2019;16(9):1374-1382. https://doi.org/10.1016/j.hrthm.2019.04.008
  31. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Accessed: December 19, 2019. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/
  32. Dmitrieva EA, Nikitin EA, Ignatova AA, Vorobyev VI, Poletaev AV, Seregina EA, Voronin KA, Polokhov DM, Maschan AA, Novichkova GA, Panteleev MA, Ptushkin VV. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. Journal of Thrombosis and Haemostasis. 2020;18(10):2672-2684. https://doi.org/10.1111/jth.14943
  33. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-2747. https://doi.org/10.1161/circulationaha.110.009449
  34. Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022;6(11):3440-3450. https://doi.org/10.1182/bloodadvances.2021006434
  35. O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncology. 2016;17(10):1409-1418. https://doi.org/10.1016/s1470-2045(16)30212-1
  36. Fraser GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Pavlovsky MA, Goy A, Mato A, Hallek M, Salman M, Tamegnon M, Sun S, Connor A, Nottage K, Schuier N, Balasubramanian S, Howes A, Cramer P. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & Lymphoma. 2020;61(13):3188-3197. https://doi.org/10.1080/10428194.2020.1795159
  37. Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology. 2023;24(5):535-552.  https://doi.org/10.1016/s1470-2045(23)00144-4
  38. Byrd JC, Woyach JA, Furman RR, Martin P, O’Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021;137(24):3327-3338. https://doi.org/10.1182/blood.2020009617
  39. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171-1175. https://doi.org/10.1038/s41375-021-01485-x
  40. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O’Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine. 2013;369(1):32-42.  https://doi.org/10.1056/nejmoa1215637
  41. IMBRUVICA. Highlights of Prescribing Information. Accessed 2013. Revised 05.2024. https://www.rxabbvie.com/pdf/imbruvica_pi.pdf
  42. CALQUENCE. Highlights of Prescribing Information. Accessed 2017. Revised 08.2022. https://www.azpicentral.com/calquence/calquence.pdf
  43. Emelina EI, Gendlin GE, Nikitin IG. Antithrombotic Therapy in Patients with Malignant Lymphoproliferative Disorders Treated with Ibrutinib. Klinicheskaya onkogematologiya. 2019;12(4):449-460. (In Russ.). https://doi.org/10.21320/2500-2139-2019-12-4-449-460
  44. Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. Journal of Thrombosis and Haemostasis. 2017;15(5):835-847.  https://doi.org/10.1111/jth.13651
  45. Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Sié P, Ysebaert L, Payrastre B. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991-3995. https://doi.org/10.1182/blood-2014-06-583294
  46. Pulte D, Olson KE, Broekman MJ, Islam N, Ballard HS, Furman RR, Olson AE, Marcus AJ. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. Journal of Translational Medicine. 2007;5:23.  https://doi.org/10.1186/1479-5876-5-23
  47. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361. https://doi.org/10.1093/ehjci/jead080
  48. Park H, Kim KH, Kim HY, Cho JY, Yoon HJ, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG. Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer. Cardiovascular Ultrasound. 2020;18(1):28.  https://doi.org/10.1186/s12947-020-00210-5
  49. Lentz R, Feinglass J, Ma S, Akhter N. Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leukemia & Lymphoma. 2019;60(6):1447-1453. https://doi.org/10.1080/10428194.2018.1533129
  50. Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology-American Society of Hematology Education Program. 2020;2020(1):336-345.  https://doi.org/10.1182/hematology.2020000118
  51. Essa H, Lodhi T, Dobson R, Wright D, Lip GYH. How to Manage Atrial Fibrillation Secondary to Ibrutinib. JACC: CardioOncology. 2021;3(1):140-144.  https://doi.org/10.1016/j.jaccao.2020.11.016
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.